Inactive Instrument

Reviva Pharmaceuticals Holdings, Inc. Nasdaq

TZAC

US76152G1004

Biotechnology & Medical Research

Tenzing Acquisition Corp. Reports Earnings Results for the Full Year Ended February 29, 2020

May 04, 2020 at 11:05 am

Tenzing Acquisition Corp. announced earnings results for the full year ended February 29, 2020. For the full year, the company announced operating loss was USD 724,740. Net income was USD 617,903.

Latest news about Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia	05-15	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Reviva Pharmaceuticals Holdings, Inc. to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference	05-13	CI
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	04-15	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15	CI
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering	11-20	MT
Reviva Pharmaceuticals Holdings, Inc. announced that it has received $2.999942 million in funding	11-19	CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	11-16	MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	11-16	MT
Sector Update: Health Care	11-16	MT
Reviva Pharmaceuticals Launching $30 Million Registered Direct Offering; Shares Fall	11-16	MT
Reviva Pharmaceuticals to Seek Acquisitions	11-16	CI
Reviva Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.999942 million in funding	11-14	CI
Reviva Pharmaceuticals Holdings Q3 Loss Widens	11-14	MT
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
HC Wainwright Raises Reviva Pharmaceuticals' Price Target to $20 From $10, Keeps Buy Rating	31/10/23	MT
Sector Update: Health Care Stocks Gain Late Afternoon	30/10/23	MT
Sector Update: Health Care	30/10/23	MT
Reviva Shares Surge After Late-Stage Schizophrenia Trial Meets Primary Endpoint	30/10/23	MT
Top Midday Gainers	30/10/23	MT
Reviva Pharmaceuticals Says Phase 3 RECOVER Trial of Brilaroxazine in Adults With Schizophrenia Meets Primary Endpoint	30/10/23	MT
Reviva Pharma's schizophrenia drug succeeds in late-stage study	30/10/23	RE
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	30/10/23	CI
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday	25/09/23	MT
Reviva Pharmaceuticals Says Last Patient Evaluated in Phase 3 Trial of Brilaroxazine to Treat Schizophrenia	25/09/23	MT

Chart Reviva Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Reviva Pharmaceuticals Holdings, Inc.

More charts

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Companyâs pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimerâs disease (BPSD), and Parkinsonâs disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Sector

Biotechnology & Medical Research

Calendar

20/05/2024 - Benchmark Healthcare House Virtual Conference

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research

Reviva Pharmaceuticals Holdings, Inc. Nasdaq

Equities

TZAC

US76152G1004

Biotechnology & Medical Research

Tenzing Acquisition Corp. Reports Earnings Results for the Full Year Ended February 29, 2020

Latest news about Reviva Pharmaceuticals Holdings, Inc.

Chart Reviva Pharmaceuticals Holdings, Inc.

Company Profile

Sector Other Biotechnology & Medical Research